Core Insights - Next Health has been selected as a key partner for Obagi Medical's ALOHA Program, focusing on personalized wellness and innovative aesthetic treatments [1] - The collaboration aims to conduct a structured assessment of Obagi's saypha MagIQ™ filler, leveraging Next Health's expertise in holistic protocols and patient-centric education [2] Company Overview - Obagi Medical is recognized for its advanced skincare solutions, with over 35 years of experience, and is the fastest-growing professional skincare brand in the U.S. as of 2024 [6][10] - Next Health, founded in 2016, specializes in health optimization and longevity, offering services like IV therapy and hormone optimization through a network of wellness centers [7] Program Details - The ALOHA Program evaluates clinical efficacy and patient experience, aiming to enhance satisfaction and loyalty through integrated Obagi protocols [3] - Standardized data will be collected across Next Health locations, with initial findings to be shared at leadership meetings and major industry conferences [3] Technology and Innovation - Obagi's saypha MagIQ™ utilizes proprietary MACRO Core Technology for a stable hyaluronic acid matrix, designed to deliver natural-looking results with high performance [4]

Alpha selected as the first Medspa platform partner given their commitment to innovation, education, and breaking through barriersNEW YORK and SACRAMENTO, Calif., Jan. 27, 2026 (GLOBE NEWSWIRE) -- Obagi Medical, a leading innovator in physician-dispensed skincare and aesthetic solutions and part of Waldencast plc (NASDAQ: WALD) (“Waldencast” or the “Company”), today announced that it has partnered with Alpha Aesthetic Partners for the Aesthetics Leadership with Obagi‘s Hyaluronic Acid (ALOHA) Program. Alpha ...

Platinum selected as the first dermatology platform partner due to its commitment to clinical evidence and dissemination across its network of practicesIn a release issued under the same headline earlier today by Waldencast plc (NASDAQ: WALD), please note that the quote by Michael Pennington in paragraph 3 was incorrect. The corrected release follows: NEW YORK and DALLAS, Jan. 26, 2026 (GLOBE NEWSWIRE) -- Obagi Medical, a leading innovator in physician-dispensed skincare and aesthetic solutions and part of ...

Core Insights - Obagi Medical has selected Platinum Dermatology Partners as the first partner for its ALOHA Program, emphasizing a commitment to clinical evidence and practice dissemination [1][5] Company Overview - Obagi Medical is a leading innovator in physician-dispensed skincare and aesthetic solutions, part of Waldencast plc, with over 35 years of experience in advanced skincare [6] - Platinum Dermatology Partners operates over 120 locations with nearly 400 providers across multiple states, focusing on exceptional dermatology practices [7] - Waldencast plc aims to build a global beauty and wellness platform by developing and scaling purpose-driven brands [8] Partnership Details - The partnership aims to generate real-world data to translate clinical safety and efficacy from FDA trials into everyday practice [2] - The ALOHA Real-World Program will provide hands-on experience with Obagi saypha MagIQ, enhancing patient satisfaction and provider relationships [3] - Initial findings from the program will be presented at the annual Platinum Summit and key industry conferences to showcase the product's real-world impact [4] Product Information - Obagi saypha MagIQ™ utilizes proprietary MACRO Core Technology for a stable hyaluronic acid matrix, designed for natural-looking results and high performance [5]

Core Insights - Obagi Medical has launched the ALOHA Program aimed at driving innovation in aesthetic practices through real-world evidence and insights [1][2] - The program will support the introduction of Obagi saypha MagIQ™, the first FDA-approved injectable hyaluronic acid filler from the company, featuring high usable HA content and a predictable injection profile [1][2] Company Overview - Obagi Medical is recognized as a leading innovator in physician-dispensed skincare with over 35 years of experience, initially known for its Obagi Nu-Derm System targeting hyperpigmentation [3] - The company is the fastest-growing professional skincare brand in the U.S. as of 2024, focusing on various skin concerns including aging, photodamage, and acne [3] Program Details - The ALOHA Program will gather real-world data from diverse practice settings to demonstrate the effectiveness of Obagi saypha MagIQ™ and its skincare products in enhancing practice success and patient satisfaction [2] - Participants in the program will provide structured feedback through standardized surveys, creating a comprehensive evaluation of the new HA injectable beyond traditional clinical trials [2] Industry Context - Waldencast plc, the parent company of Obagi Medical, aims to build a global beauty and wellness platform by developing and scaling purpose-driven brands, ensuring agility and market responsiveness [4] - The company's strategy includes leveraging operational scale and expertise in managing beauty brands to mitigate category fluctuations and enhance brand performance [4]

Core Insights - Waldencast plc has received FDA approval for Obagi saypha MagIQ™ injectable hyaluronic acid gel, marking its entry into the U.S. HA dermal filler market and aiming to double Obagi Medical's addressable market to approximately $4.2 billion by 2029 [1][2] Company Overview - Waldencast aims to build a global beauty and wellness platform by developing and scaling purpose-driven brands, with a focus on operational scale and market responsiveness [8] - Obagi Medical is recognized for its advanced skincare line with over 35 years of experience, initially known for treating hyperpigmentation [9] - Croma-Pharma GmbH, a partner in developing Obagi saypha MagIQ™, has over 40 years of expertise in HA-based treatments and has produced more than 110 million syringes [4][10] Product Details - Obagi saypha MagIQ™ utilizes proprietary MACRO Core Technology to create a stable 3D HA matrix, providing natural-looking results with high HA content and consistent gel distribution [3] - The product is expected to set a new standard in HA dermal fillers in the U.S., with a strong safety profile and proven innovation [2][5] Market Strategy - The launch of Obagi saypha MagIQ™ is planned for 2026, leveraging Obagi Medical's established network of practices and aesthetic professionals to enhance value for providers and patients [2][5] - The U.S. Nasolabial Fold pivotal study for Obagi saypha MagIQ™ included 270 patients and demonstrated non-inferiority to the control with similar safety profiles [5][6]